A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

Trial Profile

A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs L19 TNF fusion protein (Primary) ; Doxorubicin
  • Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms FIBROSARC
  • Sponsors Philogen
  • Most Recent Events

    • 07 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top